ザンジバルにおけるリウマチ性関節炎の治療:従来の抗リウマチ剤,生物学的抗リウマチ剤,標的型合成抗リウマチ剤を比較した費用対効果研究
Sanaa S Said1,2,3,4,5, Melf-Jakob Kühl6,7, Bjorg-Tilde Svanes Fevang3,8
1School of Health and Medical Sciences, The State University of Zanzibar, Zanzibar, Tanzania.
Frontiers in medicine
|September 5, 2025
まとめ
メソトレクサート単独治療はザンジバルで最も費用対効果の高い治療法です. 病気を変化させる他の抗レウマチック薬の戦略は,支払いの意思が高くなり,薬のコストが低くなり,実行可能である可能性があります.
科学分野:
- リウマトロジ
- 健康 経済
- 薬学経済学
背景:
- リウマチ性関節炎 (RA) は,サハラ以南のアフリカで治療が限られている慢性炎症性関節疾患です.
- 病気を改変する抗レウマティック薬 (DMARDs) を含む効果的な治療戦略は利用可能ですが,ザンジバルでの費用対効果は十分に確立されていません.
研究 の 目的:
- ザンジバーのRA患者に対する6つのDMARD"治療目標"戦略の費用対効果を評価する.
- 医療従事者の観点から 最も経済的に有効な治療法を特定する.
主な方法:
- マルコフモデルを用いて3年間のRA治療費用と結果をシミュレートした.
- 医療提供者の視点から費用対効果を分析し,門診費用と品質調整寿命年 (QALYs) を考慮した.
- 臨床疾患活動指数 (CDAI) を用いて有効性を測定した.
主要な成果:
- メソトレクサート単独治療の費用は634ドルからメソトレクサートと2つの生物学的/標的型合成DMARDs (b/ tsDMARDs) の費用は5011ドルに相当する.
- メソトレクサート単独療法では最低のQALY (2. 079) が得られ,b/ tsDMARDsとの併用療法では最高 (2. 209) が得られた.
- メソトレキサート単独治療は,282ドルの支払意向の値で最も費用対効果の高い戦略として特定されました.
結論:
- メソトレキサート単独治療はザンジバルで 病変性関節炎を治療するための最も費用対効果の高い選択肢です
- b/tsDMARDsを含む代替戦略は,支払意向が増加するか,薬の価格が下がれば実現可能になる可能性があります.
- 低リソースの環境でRA治療を最適化するには,臨床的有効性と経済的可能性の両方を慎重に検討する必要があります.
関連する概念動画
Rheumatic Heart Disease III: Medical Management
31
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
31
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
264
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
264
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
230
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
230
Inflammatory Bowel Disease IV: Pharmacological Management
177
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
177
The JAK-STAT Signaling Pathway
9.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.2K
Genome-wide Association Studies-GWAS
14.1K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
14.1K


